EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window

EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window

Source: 
EP Vantage
snippet: 

Earlier this year Pfizer’s oral GLP-1 agonist danuglipron looked promising in diabetes. Data presented at EASD this week, however, makes rather more disappointing reading, with tolerability looking poor at the high doses and efficacy weak at the low.